Go Pro
NYSE:AVNS

Avanos Medical Q2 2026 Earnings Report

Avanos Medical logo
$24.99 0.00 (0.00%)
As of 08/21/2026

Avanos Medical EPS Results

Actual EPS
N/A
Consensus EPS
$0.16
Beat/Miss
N/A
One Year Ago EPS
N/A

Avanos Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$173.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Avanos Medical Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Avanos Medical Earnings Headlines

Analyzing Curaleaf (OTCMKTS:CURLF) and Avanos Medical (NYSE:AVNS)
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More Avanos Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avanos Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avanos Medical and other key companies, straight to your email.

About Avanos Medical

Avanos Medical (NYSE:AVNS) is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms. These solutions are intended to help reduce reliance on systemic opioids and support accelerated recovery protocols. The enteral feeding business provides a range of feeding tubes, pumps and accessories to deliver nutrition directly to the gastrointestinal tract, serving patients with swallowing disorders or nutritional deficiencies. In respiratory care, the company’s offerings include patient interfaces, breathing circuits and related disposables that aid in noninvasive ventilation, oxygen therapy and airway management.

Avanos Medical was established as a standalone company in January 2017 following a spin-off from Kimberly-Clark’s healthcare business. Headquartered in Alpharetta, Georgia, the company maintains a presence in key markets across North America, Europe, Asia Pacific and Latin America. Its global sales and distribution network supports hospitals, surgical centers and home healthcare providers with both direct sales teams and distributor partnerships.

Under the leadership of President and Chief Executive Officer Mike Coolbaugh, Avanos pursues a strategy centered on innovation, operational excellence and targeted acquisitions to expand its product portfolio and geographic reach. The company continues to invest in research and development to advance its current offerings and explore new technologies that address evolving clinical needs in pain management, nutritional support and respiratory therapy.

View Avanos Medical Profile